Atea Pharmaceuticals (AVIR) Depreciation & Amortization (CF) (2019 - 2026)

Atea Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $104000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% year-over-year to $104000.0 in Q1 2026; TTM through Mar 2026 was $416000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $416000.0, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) held at $104000.0 in Q1 2026 per AVIR's latest filing, from $104000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $106000.0 in Q3 2022 and bottomed at $7000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $104000.0 (2022), against an average of $94823.5.
• Across the five-year window, Depreciation & Amortization (CF) soared 1414.29% in 2022 and fell 1.89% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $104000.0 in 2022, then changed by 0.0% to $104000.0 in 2023, then changed by 0.0% to $104000.0 in 2024, then changed by 0.0% to $104000.0 in 2025, then changed by 0.0% to $104000.0 in 2026.
• Per Business Quant, the three latest AVIR Depreciation & Amortization (CF) figures stand at $104000.0 (Q1 2026), $104000.0 (Q4 2025), and $104000.0 (Q3 2025).